Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 trial of Lucid-MS, its lead drug candidate for multiple sclerosis. The agreement moves Lucid-MS from planning into execution, marking a critical step in the drug's development.
Most existing MS drugs work by quieting the immune system to reduce attacks on myelin, the protective sheath around nerve fibers. Lucid-MS takes a different approach: it is designed to be neuroprotective, targeting demyelination directly rather than solely modulating the immune system. This novel mechanism could offer new hope for patients, particularly those who do not respond adequately to current therapies.
Thermo Fisher's clinical research business is a leading global contract research organization with deep expertise in central nervous system and MS studies. Its involvement lends significant credibility and operational strength to the Phase 2 trial, which will rigorously test Lucid-MS's safety and efficacy. The partnership signals confidence in Quantum's proprietary platform and could accelerate the timeline toward potential regulatory approval.
For investors, the agreement de-risks a key milestone. By enlisting a top-tier CRO, Quantum BioPharma demonstrates it is serious about advancing Lucid-MS through clinical development. Success in Phase 2 could position the company as a disruptive player in the multi-billion-dollar MS market, where demand for more effective and better-tolerated treatments remains high.
The news comes as Quantum continues to build momentum. The company's focus on neurodegenerative disorders aligns with growing scientific interest in neuroprotection as a complementary strategy to immunomodulation. If Lucid-MS proves effective, it could be used alone or in combination with existing therapies, potentially improving outcomes for millions living with MS.
Investors seeking more details can Read More>>. The latest updates on QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
This announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For full terms, see the https://www.InvestorWire.com/Disclaimer.
